Structural Analysis of the SARS-CoV-2 Spike N-Terminal Domain Across Wild-Type and Recent Variants: A Comparative Study., PMID:40485545
Is SARS-CoV-2 Spike Evolution Being Retargeted at the N-Terminal Domain?, PMID:40415355
Genome data artifacts and functional studies of deletion repair in the BA.1 SARS-CoV-2 spike protein., PMID:40308784
Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry., PMID:40285013
Spike Protein-Fibrinogen Interaction: A Novel Immune Evasion Strategy of SARS-CoV-2?, PMID:40242590
Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608
Allosteric Control and Glycan Shielding Adaptations in the SARS-CoV-2 Spike from Early to Peak Virulence., PMID:40161746
Conformational and Stability Analysis of SARS-CoV-2 Spike Protein Variants by Molecular Simulation., PMID:40137759
Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants., PMID:40136024
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability., PMID:40135879
Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern., PMID:40043139
NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants., PMID:39994733
SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals., PMID:39896663
Decoding omicron: Genetic insight into its transmission dynamics, severity spectrum and ever-evolving strategies of immune escape in comparison with other SARS-CoV-2 variants., PMID:39889436
Ancestral SARS-CoV-2 immune imprinting persists on RBD but not NTD after sequential Omicron infections., PMID:39807166
Development of a two-component recombinant vaccine for COVID-19., PMID:39759508
Enhanced antibody response to the conformational non-RBD region via DNA prime-protein boost elicits broad cross-neutralization against SARS-CoV-2 variants., PMID:39727342
Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines., PMID:39713412
Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patients., PMID:39678346
Prompt engineering-enabled LLM or MLLM and instigative bioinformatics pave the way to identify and characterize the significant SARS-CoV-2 antibody escape mutations., PMID:39657873
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV., PMID:39644492
Defining the features and structure of neutralizing antibody targeting the silent face of the SARS-CoV-2 spike N-terminal domain., PMID:39619228
Immune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain., PMID:39605558
Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV., PMID:39589795
Exploring B-cell epitope conservation and antigenicity shift in current COVID-19 variants: Analyzing spike-antibody interactions for therapeutic uses., PMID:39531907
Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies., PMID:39470577
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection., PMID:39405332
Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain., PMID:39361729
Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral families., PMID:39292703
Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants., PMID:39282390
N121T and N121S substitutions on the SARS-CoV-2 spike protein impact on serum neutralization., PMID:39221474
Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS-CoV-2 Omicron variants., PMID:39192804
Concerted deletions eliminate a neutralizing supersite in SARS-CoV-2 BA.2.87.1 spike., PMID:39173622
Recombination Events Among SARS-CoV-2 Omicron Subvariants: Impact on Spike Interaction With ACE2 Receptor and Neutralizing Antibodies., PMID:39149136
Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein., PMID:39125749
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination., PMID:39094579
Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence., PMID:39018495
Single-molecule imaging reveals allosteric stimulation of SARS-CoV-2 spike receptor binding domain by host sialic acid., PMID:39018397
Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency., PMID:38975334
Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2., PMID:38933606
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions., PMID:38900807
Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes., PMID:38848216
Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves., PMID:38793756
SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1., PMID:38779718
Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern., PMID:38766244
Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain., PMID:38740785
Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1., PMID:38616729
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV., PMID:38558973
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination., PMID:38545622
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features., PMID:38467646
For research use only. Not for human or drug use.
